

# Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)

Technology appraisal guidance

Published: 21 July 2021

[www.nice.org.uk/guidance/ta717](https://www.nice.org.uk/guidance/ta717)

# Contents

|                  |   |
|------------------|---|
| Advice.....      | 3 |
| Information..... | 3 |

## Advice

NICE is unable to make a recommendation about the use in the NHS of duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies. This is because Secura Bio has confirmed that it does not intend to make an evidence submission for the appraisal at this time. Because of limited resources, Secura Bio has chosen to focus on the greater unmet need for duvelisib in treating chronic lymphocytic leukaemia.

## Information

If NHS organisations wish to consider duvelisib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4190-2